Pacific Edge Limited
A New Zealand biotechnology company developing urine-based molecular diagnostics for bladder cancer.
Last updated August 26, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Pacific Edge Limited is a New Zealand biotechnology and medical-diagnostics company headquartered in Dunedin. The company specializes in molecular tests for bladder cancer, using genetic biomarkers identified in urine to help clinicians assess patients without relying solely on more invasive or less sensitive conventional procedures. Its principal product family is Cxbladder, a suite of urine-based diagnostic tests designed for different points in the bladder-cancer care pathway, including the evaluation of patients with symptoms, the assessment of recurrence risk, and the triage of patients who may require further investigation. Pacific Edge was founded in August 2001 and built its business around the commercial application of biomarker research. Its diagnostic approach uses RNA and protein measurements from urine samples. The company has presented this model as a potentially cost-effective alternative or complement to established methods such as cytology and cystoscopy. Because urine collection is non-invasive, the tests are intended to support earlier or more efficient clinical decision-making while reducing unnecessary procedures for some patients. The company has operated diagnostic services in New Zealand and the United States, with a United States office in Hershey, Pennsylvania, and has developed commercial relationships and partnerships in other international markets, including Australia and Europe. Its expansion strategy has depended not only on laboratory and product development but also on reimbursement coverage, clinical adoption, distribution relationships, and evidence supporting the utility of its tests in routine care. Pacific Edge became a publicly traded company with listings on the New Zealand Exchange Main Board and the Australian Securities Exchange. It undertook capital raising in 2013 and 2015 to support the development and commercialization of its diagnostic products, particularly in the United States. In June 2020, it announced a commercial relationship with Kaiser Permanente relating to its bladder-cancer tests, an important step in building access to a major United States healthcare organization. The company's performance has remained closely connected to reimbursement policy in the United States. The loss of Medicare reimbursement coverage for Cxbladder created pressure on revenue, cash reserves, and ongoing operations. In May 2026, Pacific Edge announced a new equity-raising program intended to address operating losses, support continued business operations, fund efforts to regain Medicare coverage, and provide resources for commercial expansion. The planned raise was initially described as seeking up to NZ$24 million through a placement and retail share offer; the placement was subsequently increased and the company reported raising NZ$25.4 million in new equity capital. Pacific Edge's positioning combines biotechnology, laboratory diagnostics, and precision-medicine applications. Rather than selling a broad portfolio of consumer healthcare products, it focuses on specialized tests that provide information to urologists, oncologists, and other clinicians treating or evaluating bladder cancer. Its principal commercial challenge is translating biomarker performance into sustained clinical use and payer reimbursement across multiple healthcare systems.
History
Pacific Edge Limited was established in August 2001 in Dunedin, New Zealand, as a biotechnology company focused on applying molecular-biomarker research to cancer diagnosis. Its central scientific and commercial proposition was that urine contains measurable genetic signals that can assist in identifying or monitoring bladder cancer. This approach allowed the company to develop tests based on a non-invasive sample rather than depending exclusively on procedures such as cystoscopy or conventional cytology. The company developed the Cxbladder family as its principal diagnostic platform. Cxbladder tests use molecular assays involving RNA and protein biomarkers and are designed for distinct clinical purposes. Depending on the product and use case, the tests can help assess patients presenting with urinary symptoms, support the evaluation of possible bladder cancer, or assist with decisions concerning recurrence and the need for additional investigation. Pacific Edge has positioned the platform as a means of improving sensitivity and clinical efficiency while potentially reducing unnecessary invasive procedures. During the 2010s, Pacific Edge pursued commercialization and international growth. It became listed on the New Zealand Exchange Main Board and the Australian Securities Exchange and raised capital in 2013 and 2015. Those financings were directed toward advancing the company's diagnostic technology and building the infrastructure needed to commercialize Cxbladder, particularly in the United States. The company's operating model included diagnostic services in New Zealand and the United States, while partnerships and commercial relationships extended its reach into Australia and Europe. Pacific Edge's United States strategy required more than regulatory and clinical development. The company also needed healthcare providers, laboratories, insurers, and other payers to recognize and reimburse its tests. In June 2020, it announced a commercial relationship with Kaiser Permanente, one of the largest healthcare organizations in the United States. The relationship represented an effort to broaden the use of Cxbladder within an important healthcare network and to establish the test as part of real-world bladder-cancer assessment. Reimbursement policy later became a major determinant of the company's financial position. The loss of Medicare reimbursement coverage for Cxbladder tests in the United States weakened the company's revenue outlook and contributed to operating losses and declining cash reserves. This demonstrated the dependence of specialized diagnostic businesses on payer decisions: even when a test remains commercially and clinically available, restricted reimbursement can materially affect adoption and cash generation. In May 2026, Pacific Edge announced a further equity-raising initiative intended to maintain operations, support efforts to regain Medicare coverage, and finance the commercial expansion of its diagnostic products. The proposal was initially described as seeking up to NZ$24 million through a placement and retail share offer. The placement was subsequently increased, and the company reported raising NZ$25.4 million in new equity capital. The financing reflected the company's continuing effort to preserve its diagnostic platform and commercial presence while addressing the consequences of reimbursement changes. Pacific Edge remains a focused biotechnology and diagnostics business rather than a diversified healthcare group. Its identity is closely associated with Cxbladder and with the use of urine-based genetic biomarkers in bladder-cancer care. Its long-term prospects depend on clinical evidence, physician adoption, laboratory operations, payer coverage, regulatory conditions, and the ability to fund commercialization across its target markets.
- 2026
NZ$25.4 million equity raising
[1]Following the loss of United States Medicare reimbursement coverage for Cxbladder, Pacific Edge increased its proposed placement and reported raising NZ$25.4 million in new equity capital.
- 2020
Kaiser Permanente commercial relationship
[1]Pacific Edge announced a commercial relationship with Kaiser Permanente for its bladder-cancer tests.
- 2016
Medical technology innovation award
[1]Pacific Edge received a Medical Technology Association of New Zealand Innovation Award.
- 2015
Further capital raising
[1]The company completed another capital-raising initiative aimed at advancing the United States commercialization of its diagnostic tests.
- 2014
NZBIO Biotech Company of the Year
[1]Pacific Edge received the NZBIO Biotech Company of the Year award.
- 2013
Capital raising to support commercialization
[1]Pacific Edge undertook a capital-raising initiative to advance its diagnostic products and support their commercialization, particularly in the United States.
- 2001
Company founded
[1]Pacific Edge was founded in August 2001 in Dunedin, New Zealand, to develop biotechnology applications based on cancer biomarkers.
Products and positioning
A specialist molecular-diagnostics company focused on non-invasive urine testing for bladder-cancer detection, recurrence assessment, and clinical triage.
Bladder-cancer molecular diagnostics
Cxbladder
Cxbladder is Pacific Edge's suite of urine-based molecular diagnostic tests for bladder-cancer care. The platform analyzes genetic and protein biomarkers in urine and includes specialized tests intended for different clinical situations, such as evaluating patients with urinary symptoms, supporting the detection of cancer, assessing recurrence risk, and helping clinicians decide whether further investigation is warranted. Its non-invasive sample collection and emphasis on biomarker-based information distinguish it from diagnostic pathways that rely primarily on cytology or invasive examination.
Brand decisions
2026
Equity raising after Medicare reimbursement lossStrategyBackground
The loss of United States Medicare reimbursement coverage for Cxbladder contributed to operating losses and declining cash reserves.
Action taken
Pacific Edge proposed a placement and retail share offer, initially seeking up to NZ$24 million, then increased the placement and raised NZ$25.4 million in new equity capital.
Aftermath
The company stated that the proceeds would support ongoing operations, efforts to regain Medicare coverage, and commercial expansion of its diagnostic products.
New equity capital raised. Proposed raise of up to NZ$24 million → NZ$25.4 million raised (2026)
2020
Commercial relationship with Kaiser PermanenteStrategyBackground
Pacific Edge sought to expand access to Cxbladder through relationships with major healthcare organizations in the United States.
Action taken
The company entered into a commercial relationship with Kaiser Permanente involving its bladder-cancer tests.
Aftermath
The relationship strengthened Pacific Edge's commercial presence within the United States healthcare market.
2015
Additional funding for United States expansionStrategyBackground
Pacific Edge continued to pursue the clinical and commercial development of its diagnostic tests in the United States.
Action taken
The company conducted a further capital raising to advance commercialization of its products.
Aftermath
The financing supported the company's continuing international commercialization program.
2013
Capital raising for diagnostic commercializationStrategyBackground
Pacific Edge required additional capital to develop and commercialize its bladder-cancer diagnostic products, with particular emphasis on the United States market.
Action taken
The company undertook a capital-raising initiative to support commercialization and related business development.
Aftermath
The financing formed part of the company's broader effort to establish Cxbladder as an international diagnostic product.
Recent events
Pacific Edge appoints Peter Meintjes as chief executive[2]
Reported:
Pacific Edge appointed Peter Meintjes as its new chief executive; he will operate from the company's Dunedin base.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/pacific-edge-limited · Editorial policy · How profiles are compiled